Therapeutic antibodies for prostate cancer

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Monoclonal antibodies (mAbs) were initially conceived as targeted delivery systems for radioisotopes, toxins, or drugs to tumors.
• The understanding of therapeutic antibodies has evolved, recognizing their potential as effector molecules that elicit antitumor responses.

Purpose of the Study:

• To review the evolution of antibody-based therapies from carrier molecules to effector molecules.
• To discuss current antibody-based strategies under investigation for prostate cancer treatment.

Main Methods:

• Review of historical developments in antibody technology and clinical trials.
• Analysis of current research and emerging strategies in antibody-based cancer therapy.

Main Results:

• Therapeutic antibodies possess broad potential beyond targeted delivery, capable of initiating antitumor immune responses.
• Numerous obstacles in antibody therapy are being addressed through technological advancements and strategic development.

Conclusions:

• Antibody-based products have unlimited utility and versatility in cancer treatment.
• Ongoing clinical trials are evaluating various antibody strategies for prostate cancer, indicating significant progress in the field.